Molecular Weight: | 413.47 |
Formula: | C24H23N5O2 |
Purity: | ≥98% |
CAS#: | 1542705-92-9 |
Solubility: | DMSO up to 100 mM |
Chemical Name: | 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide |
Storage: | Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year. |
Biological Activity:
CB-5083 is a highly potent, selective and orally bioavailable p97 AAA ATPase inhibitor with IC50 ~11 nM. Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins, retention of endoplasmic reticulum-associated degradation (ERAD) substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response. In xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematological and solid tumor models.
How to Use:
In vitro: CB-5083 was used at 1-2.5 µM final concentration in various assays.
In vivo: CB-5083 was dosed to mice orally at 25-100 mg/Kg once or twice per day.
Reference:
- 1. Zhou HJ, et al. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). (2015) J Med Chem. 58(24):9480-97.
- 2. Anderson DJ, et al. Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. (2015) Cancer Cell. 28(5):653-65.
Products are for research use only. Not for human use.